ohsu main banner HomeAboutResearch ButtonFacultyResourcesGrants and AwardsNews and EventsSeminarsGraduate ProgramOpportunitiesContributeContact VGTIwelcome bannershodow image
donate here

VGTI in the News

The Art of Self- Defence (Nature) (click to download)

OVERVIEW

The Vaccine and Gene Therapy Institute (VGTI) at Oregon Health & Science University (OHSU) has assembled a multidisciplinary team of scientists to respond to serious viral disease threats, including AIDS, chronic viral infection-associated diseases, newly emerging viral diseases and infectious diseases of the elderly. Our Programs are intended to span the continuum between basic and clinical science, in which discoveries are rapidly advanced from the level of molecular and cellular biology through animal models and ultimately into clinical testing. The development of this unique program in immunology and virology provides an important training opportunity for graduate students and postdoctoral fellows at OHSU. This is why an important part of our mission is the training of young scientists in newer academic disciplines emerging at the VGTI.

RESOURCES:

The VGTI is a free 60,000 sq. ft. standing facility: 4 Biosafety Level 3 (BSL3) and 2 Animal Biosafety Level 3 (ABSL3) laboratories, several core services, including the Gene Microarray Shared Resource, a clinical vaccine testing core, a state of the art flow cytometry core, monoclonal core, virology core, imaging core with a laser capture microscope, mass spectrometry core and animal core. The ONPRC animal core provides access to over 4500 rhesus macaques, the largest accumulation of specific pathogen free animals in the primate centers, a large colony of aged monkeys, and ABSL3 containment for over 250 monkeys in additional to housing other small animal species.

100 Employees, 10 Students
Annual funding of $25MM
Number of Company Spinouts: 1:

View our latest publications.

B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers

Nature Medicine 21, 132–139 (2015)

(Click here for full text)

HIV: Seeking ultimate victory

Nature 517, 281–282 (15 January 2015)

(Click here for full text)

Novel vaccine vectors for HIV-1

Nature Reviews Microbiology 12, 765–771 (2014)

(Click here for full text)

Are effector memory T cells the key to an effective HIV/AIDS vaccine?

Embo Reports Vol. 15, Issue 8, 817 – 910 (2014)

(Click here for full text)

Science Cover
 


Cytomegalovirus pp65 limits dissemination but is dispensable for persistence

J Clin Invest.
124(5):1928–1944

(Click here for full text)

 

Cytomegalovirus miRNAs Target Secretory Pathway Genes to Facilitate Formation of the Virion Assembly Compartment and Reduce Cytokine Secretion

Cell Host Microb Vol. 15 Issue 3 363-73

(Click here for full text)

Science Cover

HIV: Antibodies advance the search for a cure

 

Nature 503, Issue 7475 207-208

(Click here for full text)

 

Immune clearance of highly pathogenic SIV infection

 

Nature 502, Issue 7469 100-104

(Click here for full text)

Science Cover

Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms

Science Vol. 340 no. 6135

(Click here for full text)

Profound early control of highly pathogenic SIV
by an effector memory T-cell vaccine

Nature / Vol 473 / Issue No 7348 Page 523

(Click here for PubMed link)

Evasion of CD8+ T Cells Is Critical for Superinfection by
Cytomegalovirus

Science Vol. 328. no. 5974, pp. 102 - 106

(Click here for full text)

Cowpox Virus Inhibits the Transporter Associated with Antigen Processing to Evade T Cell Recognition

Cell Host & Microbe, Volume 6, Issue 5, 433-445, 19

(Click here for PubMed link)

Effector memory T cell responses are associated with
protection of rhesus monkeys from mucosal simian
immunodeficiency virus challenge

Nature Medicine 15, 293 - 299

(Click here for full text)